Literature DB >> 12374046

[Cyclosporin A in atopic dermatitis].

Miguel Angel Cordero Miranda1, Begonia Casas Becerra, Norma Isabel Reyes Ruiz, Lourdes Avila Castañón, Blanca Estela del Río Navarro, Juan José Luis Sienra Monge.   

Abstract

Atopic dermatitis is a chronic inflammatory skin disease, with inherited predisposition. It has typical morphology and distribution. Patients generally can be controlled with the use of moisturizers and topical steroids. In severe cases, it is recommended the use of alternative management. Cyclosporine is an immunosuppressor drug which inhibit the expression of T activated cells. Many open and placebo-controlled trials have been made evaluating its use, efficacy and security, in adults and children. The results suggest an initial dose of 5-6 mg/kg per day and reducing the amount according to response (load dose and maintenance dose) at long term in order to reach complete remission after withdrawal of treatment and limit adverse effects, like renal toxicity and hypertension. The immunological changes in AD patients treated with cyclosporine include eosinophil count reduction, besides lower levels of E-selectin, and soluble CD30 (known as disease markers), but overall, it corrects the imbalance between Th1 and Th2 response present in these kinds of diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12374046

Source DB:  PubMed          Journal:  Rev Alerg Mex        ISSN: 0002-5151


  2 in total

1.  Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt.

Authors:  Mohamed A El-Khalawany; Hatem Hassan; Dalia Shaaban; Noha Ghonaim; Bayoumi Eassa
Journal:  Eur J Pediatr       Date:  2012-11-16       Impact factor: 3.183

2.  Evaluation of Association Between the Serum Levels of MMP-9 and MMP-9/TIMPs With Soluble Forms of Selectins and Itching Induced by Sulfur Mustard.

Authors:  Nayere Askari; Tooba Ghazanfari; Mohammad Mehdi Naghizadeh; Athar Moin; Ali Khamesipour; Shahryar Pourfarzam; Zuhair Mohammad Hassan
Journal:  Iran J Pathol       Date:  2017-01-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.